BOOST Pharma Will Present Therapy Update in Phoenix
CEO Hans Schambye will detail progress on a new stem cell therapy at an upcoming industry conference in Phoenix.
Updated on Sept. 24, 2026 in Biotech
Live Poll
Is now a good time to invest in early-stage medical companies ahead of final clinical trials?
On October 6, 2026, BOOST Pharma CEO Hans Schambye will present clinical updates on the stem cell therapy BT-101 at the Cell & Gene Meeting on the Mesa in Phoenix. The presentation takes place at the Arizona Biltmore Hotel as part of the company selection as a 2026 Innovation Spotlight company.
Why it matters
The company aims to highlight clinical success and engage with investors to support the upcoming transition into a pivotal Phase III study for its bone disorder treatment. Currently, there are no FDA- or EMA-approved therapies available for patients suffering from osteogenesis imperfecta.
BT-101 is an off-the-shelf allogeneic stem cell therapy designed to treat osteogenesis imperfecta, a condition affecting an estimated 1 in 15,000 people globally. The treatment has already received Orphan Drug Designation in both the United States and Europe.
The players
BOOST Pharma
This is a clinical-stage biopharmaceutical company focused on developing stem cell therapies.
Hans Schambye
He is the CEO of BOOST Pharma and a featured speaker at upcoming industry regenerative medicine summits.
The details
The program update focuses on the clinical performance of BT-101, which has demonstrated significant potential in reducing fracture frequency among study participants. Schambye will provide these insights while meeting with stakeholders to discuss the future regulatory and development path for the drug.
Timeline
October 4, 2026: CEO Hans Schambye attends the Alliance for Regenerative Medicine CEO Summit.
October 5-7, 2026: The Cell & Gene Meeting on the Mesa takes place in Phoenix.
October 6, 2026: Hans Schambye presents the BT-101 program update at the Arizona Biltmore Hotel.
The Tech Race
BT-101 follows the industry pattern of utilizing Orphan Drug Designation to accelerate the development pathway for rare disease therapeutics. This approach positions the company within a competitive field of innovators seeking to address previously untreatable genetic conditions.
The potential future approval of this therapy would provide the first clinically approved treatment option for individuals living with osteogenesis imperfecta. If successful, the move into Phase III development represents a significant step toward making this novel treatment available to the public.
The takeaway
The development of BT-101 highlights the critical role of innovation in addressing rare, previously unmanaged genetic bone disorders. Patients and families affected by these conditions should follow future clinical milestones as the therapy progresses toward larger trials.
Further reading
Learn more about the latest industry developments in the Biotech section.
More information
For more details on the company's research pipeline, visit the BOOST Pharma corporate website.
Source note: This article includes information reported by The Manila times.
Live Poll
Is now a good time to invest in early-stage medical companies ahead of final clinical trials?
